# Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

> **NCT00919763** · PHASE2 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 102 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** CD2027 Ointment 3 mcg/g, twice daily
- **DRUG:** Vehicle Ointment, twice daily

## Key facts

- **NCT ID:** NCT00919763
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05-21
- **Primary completion:** 2009-10-01
- **Final completion:** 2009-10-01
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2022-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00919763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00919763, "Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00919763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*